Gabapentin Treatment of Mood Disorders: A Preliminary Study
J Clin Psychiatry 1998;59(8):426-429
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To determine if gabapentin is effective either as adjunctive
treatment or as monotherapy for major affective disorders in a naturalistic setting.
Method: All charts of patients meeting DSM-IV criteria for bipolar
disorder or unipolar major depressive disorder treated with gabapentin in a private
psychiatric practice were reviewed and clinical response was assessed retrospectively
using the Clinical Global Impressions scale for Improvement (CGI-I).
Results: Gabapentin was moderately to markedly effective in 30% (15/50)
of patients, with statistically nonsignificant differences between patients with bipolar
disorder type I, bipolar disorder type II and NOS, and unipolar major depressive disorder.
70% reported side effects, mainly sedation, with 16% of the total sample discontinuing
treatment due to adverse events.
Conclusion: Gabapentin appears to be somewhat effective as add-on
treatment in a subgroup of patients with mood disorders in a naturalistic setting.
Prospective, controlled studies are required to clarify these pilot data.